what is betfred
No. 13 Providence sweeps Cumberlands, advances to NAIA volleyball final site
Frontier Conference Player of the Year Bella Thompson and White Sulphur Springs native Cabry Taylor were mobbed near mid-court Saturday after blocking a match-clinching shot to propel Providence in the NAIA Volleyball National Championship Tournament. The No. 13-ranked Argos swept Cumberlands (Ky.) 25-13, 25-23, 25-20 to secure their first spot at Sioux City’s final site since reaching the quarterfinals in 2021. NAIA All-American Sadie Giles and junior Bella Green paced the Argos with seven kills apiece. Bozeman Gallatin graduate Ryann Eddins totaled six kills, sparking a second-set comeback that saw Providence score nine of the set’s final 11 points to erase a five-point deficit. Giles produced the equalizing kill in that second set, then provided a critical one a set later when Cumberlands pulled within two points. Thompson, who entered play with over 1,200 assists this season, supplied 25 more in victory. Senior Ava Saiers, the Frontier Newcomer of the Year from Adams State, led all players with five aces and matched Giles’ 12 digs. Thompson and Taylor totaled 10 blocks and combined for eight kills. Saturday represented Providence’s eighth all-time playoff victory, advancing the Argos, the Frontier’s automatic playoff bid, to 26-6 overall. Providence has now won seven straight overall and improved to 11-1 at home. Final site play begins on Dec. 3 in Sioux City, Iowa.The US says it pushed retraction of a famine warning for north Gaza. Aid groups express concern.
UN expert: Myanmar's desperate military ramps up attacks including beheadings, rapes and tortureThe news of the missing female master’s student being found has brought a mixture of relief and distress to the public. While the immediate concern for her safety has been alleviated, the details of her ordeal and the involvement of others have raised troubling implications and doubts about the motives behind her disappearance.
Ohanaeze Ndigbo picks Umahi as 2024 Igbo Man of the YearCharlize Theron Joins Cast of Christopher Nolan’s Next Movie
Dodgers $85 million fan-favorite could soon betray LA in favor of Braves | Sporting News
Biotech stocks, particularly in the small- and mid-cap space, were hot topics among retail investors in 2024, often spurred by major announcements or clinical developments. Collectively, these stocks attracted significant chatter on Stocktwits. Here are the top five biotech stocks with the highest message volume growth this year: Tonix Pharmaceuticals Holding Corp. (TNXP) : +47,066% Message Volume Tonix focuses on developing therapies to treat and prevent diseases. Its TNX-102 SL, a non-opioid analgesic for fibromyalgia, gained attention when the FDA accepted its New Drug Application in December. Earlier in the year, the company also reiterated its commitment to developing an mpox vaccine. Despite these milestones, TNXP shares are down over 97% this year. Candel Therapeutics Inc. (CADL) : +16,000% Message Volume Candel develops viral immunotherapies targeting cancer. Its lead product, CAN-2409, is under trial for various cancers, including prostate and non-small cell lung cancer. Positive late-stage results released this month for CAN-2409 in prostate cancer drove retail interest. Shares of CADL are up over 500% this year. Cardio Diagnostics Holdings Inc. (CDIO) : +11,650% Message Volume Cardio Diagnostics gained traction with its AI-powered PrecisionCHD test for coronary heart disease. The test demonstrated significant cost-saving potential in healthcare, according to the company. Cardio also received final pricing determinations from the Centers for Medicare & Medicaid Services for its products. Its stock has fallen nearly 63% year-to-date. Recursion Pharmaceuticals Inc. (RXRX) : +9,600% Message Volume Recursion uses AI and automation to discover medicines. A $50 million investment from Nvidia to support AI-driven drug discovery efforts primarily sparked significant retail interest this year, although RXRX shares have declined 22% so far in 2024. Galectin Therapeutics Inc. (GALT) : +5,800% Message Volume Galectin’s focus on fibrotic and inflammatory diseases, led by its drug belapectin, caught investors’ attention despite mixed trial results. While the drug didn’t meet statistical significance for a key endpoint in an early liver disease trial, further data analysis is expected in early 2025. GALT shares are down over 48% this year. For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Few people in politics inspire the kind of respect Sardar Manmohan Singh did Priyanka